Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Sirius Starts Phase I Trial in Australia of siRNA Aimed at Thromboembolic Disorders

publication date: Feb 5, 2024

Sirius Therapeutics has dosed the first healthy volunteer in an Australian Phase I, first-in-human clinical trial of its next-gen siRNA candidate aimed at preventing and treating thromboembolic disorders. SRSD107 targets coagulation Factor XI (FXI). Recently, Sirius started a China Phase I trial of SRSD101 to treat dyslipidemia. Sirius, which has a Research Center in San Diego and a Translational Center in Shanghai, believes RNAi medicines offer an expanded range of drug targets with durable efficacy that could address existing unmet needs. In late 2023, Sirius closed a $60 million Series-B financing. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital